Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM095HQ)

Drug Name
LM11A-31 Drug Info
Synonyms
N-[2-(Morpholin-4-yl)ethyl]-L-isoleucinamide; 1243259-19-9; (2S,3S)-2-amino-3-methyl-N-(2-morpholin-4-ylethyl)pentanamide; 102562-74-3; SCHEMBL1723692; DTXSID50595097; ZINC4239960; (2s,3s)-2-amino-3-methyl-N-(2-morpholinoethyl) pentanamide; (2S,3S)-2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide; (2S,3S)-2-Amino-3-methyl-N-(2-morpholinoethyl)pentanamide
Indication
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Phase 1/2 [1]
Cross-matching ID
PubChem CID
18604758
CAS Number
CAS 1243259-19-9
TTD Drug ID
DM095HQ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Low-affinity nerve growth factor receptor (NGFR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cenegermin DM8Y2RU Neurotrophic keratitis 9A74 Approved [3]
Fulranumab DMK38MV Arthralgia ME82 Phase 3 [4]
SPI-205 DMHC2AW Parkinson disease 8A00.0 Phase 2 [5]
Org-2766 DMVRA8N Cognitive impairment 6D71 Discontinued in Phase 3 [6]
BU-4514N DMJDMTK Alzheimer disease 8A20 Terminated [7]
ReN-1820 DMWIAUK Cystitis GC00 Terminated [8]
CEP-427 DMTI10C Alzheimer disease 8A20 Terminated [4]
TDI-0059 DMSI9QM Motor neurone disease 8B60 Investigative [4]
Nerve growth factor conjugated RAP peptide DM3AW8X Neurodegenerative disorder 8A20-8A23 Investigative [4]
ALD-901 DMAYGK9 Pain MG30-MG3Z Investigative [4]
Cenegermin DM8Y2RU Neurotrophic keratitis 9A74 Approved [3]
Fulranumab DMK38MV Arthralgia ME82 Phase 3 [4]
SPI-205 DMHC2AW Parkinson disease 8A00.0 Phase 2 [5]
Org-2766 DMVRA8N Cognitive impairment 6D71 Discontinued in Phase 3 [6]
BU-4514N DMJDMTK Alzheimer disease 8A20 Terminated [7]
ReN-1820 DMWIAUK Cystitis GC00 Terminated [8]
CEP-427 DMTI10C Alzheimer disease 8A20 Terminated [4]
TDI-0059 DMSI9QM Motor neurone disease 8B60 Investigative [4]
Nerve growth factor conjugated RAP peptide DM3AW8X Neurodegenerative disorder 8A20-8A23 Investigative [4]
ALD-901 DMAYGK9 Pain MG30-MG3Z Investigative [4]
⏷ Show the Full List of 20 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Low-affinity nerve growth factor receptor (NGFR) TTEDJN4 TNR16_HUMAN Modulator [2]

References

1 ClinicalTrials.gov (NCT03069014) Study of LM11A-31-BHS in Mild-moderate AD Patients. U.S. National Institutes of Health.
2 Small molecule p75NTR ligand prevents cognitive deficits and neurite degeneration in an Alzheimer's mouse model.Neurobiol Aging.2013 Aug;34(8):2052-63.
3 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1888).
5 AIT-082 NeoTherapeutics Inc. IDrugs. 1998 Oct;1(6):694-9.
6 Effects of the ACTH4-9 analog Org2766 on brain plasticity: modulation of excitatory neurotransmission. Psychoneuroendocrinology. 1992 Aug;17(4):315-25.
7 A new neuritogenetic compound BU-4514N produced by Microtetraspora sp. J Antibiot (Tokyo). 1993 Jun;46(6):875-83.
8 Phosphorylation of Extracellular Signal-Regulated Kinases (pERK1/2) in Bladder Afferent Pathways with Cyclophosphamide (CYP)-Induced Cystitis. Neuroscience. 2009 November 10; 163(4): 1353-1362.